Company Filing History:
1 out of 45 
1 out of 4 
1 out of 3 Years Active: 2025
Title: The Innovative Contributions of Jordi Minguillón Pedreño
Introduction
Jordi Minguillón Pedreño is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of cancer treatment through his innovative research and patents. His work focuses on the therapeutic use of afatinib, a drug that has shown promise in treating cancers associated with DNA damage repair defects.
Latest Patents
Minguillón Pedreño holds a patent for the therapeutic use of afatinib in cancer treatment. The invention provides afatinib or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of cancer in patients suffering from diseases caused by defects in DNA damage repair mechanisms. Remarkably, when afatinib was administered to Fanconi Anemia (FA) cells, it demonstrated a therapeutic anti-cancer effect without any toxic side effects on DNA.
Career Highlights
Throughout his career, Minguillón Pedreño has been associated with prestigious institutions such as Universitat Autònoma de Barcelona and the Consorcio Centro de Investigación Biomédica en Red. His work in these organizations has contributed to advancing biomedical research and cancer therapies.
Collaborations
Minguillón Pedreño has collaborated with esteemed colleagues, including Jordi Surrallés Calonge and Helena Montanuy Escribano. These collaborations have further enriched his research and innovation in the field of cancer treatment.
Conclusion
Jordi Minguillón Pedreño's contributions to cancer research through his patent on afatinib highlight his role as an influential inventor in the medical field. His work continues to inspire advancements in therapeutic strategies for cancer treatment.